Teva and Blackstone Life Sciences strike $400m deal to advance promising IBD therapy
The funding will be spread over four years, with BXLS also eligible for regulatory and commercial milestones, plus royalties on worldwide sales
The funding will be spread over four years, with BXLS also eligible for regulatory and commercial milestones, plus royalties on worldwide sales
The investment will accelerate the overall Sarclisa development program
Subscribe To Our Newsletter & Stay Updated